Literature DB >> 20409916

Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A1-7)3292 rats.

Ana Paula Nadu1, Anderson J Ferreira, Timothy L Reudelhuber, Michael Bader, Robson A S Santos.   

Abstract

We investigated the expression of specific extracellular matrix (ECM) proteins in cardiac hypertrophy induced by isoproterenol in TGR(A1-7)3292 rats. Additionally, changes in circulating and tissue renin-angiotensin system (RAS) were analyzed. Left ventricles (LV) were used for quantification of collagen type I, III, and fibronectin using immunofluorescence-labeling techniques. Angiotensin (Ang) II levels were measured by radioimmunoassay. Expression of RAS components was assessed by semi-quantitative polymerase chain reaction (PCR) or real-time PCR. Isoproterenol treatment induced an increase in the expression of collagen I, III, and fibronectin in normal rats. Collagen I and fibronectin expression were decreased in TGR(A1-7)3292 at basal conditions and both proteins increased by isoproterenol treatment; however, the levels achieved were still significantly lower than those observed in treated normal rats. The increase in collagen III observed in normal rats was completely blunted in TGR(A1-7)3292. Moreover, TGR(A1-7)3292 presented lower Ang II levels and angiotensinogen expression and a higher angiotensin-converting enzyme 2 (ACE2) expression in LV. Isoproterenol treatment increased cardiac Ang II concentration only in normal rats, which was associated with an increase in ACE2 and a decrease in Mas expression. These observations suggest that Ang-(1-7) specifically modulates the expression of RAS components and ECM proteins in LV.

Entities:  

Year:  2008        PMID: 20409916     DOI: 10.1016/j.jash.2008.04.012

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  12 in total

Review 1.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

Review 2.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

3.  Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors.

Authors:  Y Y Chen; D Liu; P Zhang; J C Zhong; C J Zhang; S L Wu; Y Q Zhang; G Z Liu; M He; L J Jin; H M Yu
Journal:  J Hum Hypertens       Date:  2016-04-28       Impact factor: 3.012

4.  Fibronectin contributes to pathological cardiac hypertrophy but not physiological growth.

Authors:  Mathias H Konstandin; Mirko Völkers; Brett Collins; Pearl Quijada; Mercedes Quintana; Andrea De La Torre; Lucy Ormachea; Shabana Din; Natalie Gude; Haruhiro Toko; Mark A Sussman
Journal:  Basic Res Cardiol       Date:  2013-08-04       Impact factor: 17.165

5.  Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor.

Authors:  Monica Flores-Muñoz; Bruno M D C Godinho; Abdulaziz Almalik; Stuart A Nicklin
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

6.  New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis.

Authors:  Anderson J Ferreira; Tatiane M Murça; Rodrigo A Fraga-Silva; Carlos Henrique Castro; Mohan K Raizada; Robson A S Santos
Journal:  Int J Hypertens       Date:  2012-01-26       Impact factor: 2.420

Review 7.  ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations.

Authors:  Eric M Snyder; Bruce D Johnson
Journal:  Pharmacogenomics       Date:  2020-06-05       Impact factor: 2.533

8.  The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats.

Authors:  Sílvia Q Savergnini; Danielle Ianzer; Mariana B L Carvalho; Anderson J Ferreira; Gerluza A B Silva; Fúlvia D Marques; Antônio Augusto B Peluso; Merav Beiman; Gady Cojocaru; Yossi Cohen; Alvair P Almeida; Galit Rotman; Robson A S Santos
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

9.  Amelioration of cardiac function and activation of anti-inflammatory vasoactive peptides expression in the rat myocardium by low level laser therapy.

Authors:  Martha Trindade Manchini; Andrey Jorge Serra; Regiane dos Santos Feliciano; Eduardo Tadeu Santana; Ednei Luis Antônio; Paulo de Tarso Camillo de Carvalho; Jairo Montemor; Renato Oliveira Crajoinas; Adriana Castello Costa Girardi; Paulo José Ferreira Tucci; José Antônio Silva
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

10.  Effect of Angiotensin(1-7) on Heart Function in an Experimental Rat Model of Obesity.

Authors:  Katja Blanke; Franziska Schlegel; Walter Raasch; Michael Bader; Ingo Dähnert; Stefan Dhein; Aida Salameh
Journal:  Front Physiol       Date:  2015-12-21       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.